In this episode of Med Tech Talks, Robert Klupacs is joined by Dr Megan Baldwin, Founder, Chief Innovation Officer and Executive Director of Opthea Limited. 

Opthea limited is a global biopharmaceutical company aspiring to become the leader of therapeutic innovation in retinal diseases. They have a world class team of ophthalmology experts working to develop breakthrough therapies for those who suffer from retinal disease.  

Megan has over 20 years of experience focusing on angiogenesis and therapeutic strategies for cancer and ophthalmic indications. With a PhD in medicine from the University of Melbourne, and having conducted her postdoctoral studies at Genentech, Megan joined Circadian Technologies Limited, now Opthea, in 2008 as Head of Preclinical R&D, and became Chief Executive in 2014. Today, she's a member of the Australian Institute for Company Directors, a board member of AusBiotech and serves on the boards of public and private companies.

In this episode you will hear about: 

• How Opthea is working to improve outcomes for patients with wet AMD. 
• Insight into Opthea’s strategy for attracting investment in its early-stage research and beyond  
• What Megan thinks Australia needs to do in order to support translation of Australian innovation 
• Megan’s advice for seeking mentorship and the importance of looking outside of your network. 

 Learn more about Opthea. 

 Read about Megan Baldwin.  

Updated version 05/08/22

In the latest episode of Med Tech Talks, Robert Klupacs is joined by Bronwyn Le Grice, CEO and Managing Director of ANDHealth.

Bronwyn has over 20 years executive experience in health technology commercialisation, venture capital, capital raising and industry advocacy.  

In 2017, she founded ANDHealth – which is now one of Australia’s leading health technology commercialisation organisations.  

It’s flagship ANDHealth+ program has a successful track record in taking businesses to scale, with companies selected in the program raising over $150 million in dilutive and non-dilutive funding, creating 400+ jobs, undertaking 72 clinical studies and impacting over 700,000 patients over the past 6 years. 

In this episode, you will learn more about: 

• How digital health technology could shape the future of health care.
• Opportunities digital health provides to increase efficiency of care.
• Advice for digital health companies thinking of being part of an incubator or accelerator.
• Some of the key challenges faced by Australia in building  a world class digital health industry.

Discover more about ANDHealth.

Read about Bronwyn Le Grice

Updated version 05/08/22

In the latest episode of Med Tech Talks, Robert Klupacs is joined by Professor Andrew Wilks and Dr Chris Burns.

Professor Wilks and Dr Burns are two research leaders who were involved in the incredible breakthrough of the drug, Momelotinib, which has emerged as a treatment for myelofibrosis – a rare type of bone marrow cancer.

In this episode you will hear about:

• The journey of momelotinib from bench top to a commercial product
• Professor Wilks and Dr Burns' experience as entrepreneurs
• Where momelotinib is today and the legacy of the Australian research effort.

More information:

Learn more about Professor Andrew Wilks
 
Find out more about Dr Chris Burns

Updated version 05/08/22

In the latest episode of Med Tech Talks, Robert Klupacs is joined by Professor Moira O'Bryan, Dean of the Faculty of Science at the University of Melbourne.

Professor O'Bryan specialises in andrology and through her impressive research career, she has recently been given the prestigious role of a Dean at the Unversity of Melbourne which is ranked as the 14th best preforming university in the world per the QS rankings.

In this episode you will hear about:

• Moira's journey to becoming Dean of the Faculty of Science at the University of Melbourne
• Could the male contraceptive pill be a reality?
• Her thoughts on how the University of Melbourne can be a leader in innovation for Australia.

More information:

Learn more about Professor Moira O'Bryan.
Visit the University of Melbourne website.

Updated version 05/08/22

In the latest episode of Med Tech Talks, we present a special keynote speech from Dr Andres Fouras, Founding CEO of 4DMedical, recorded at the Bionics Institute 2023 Innovation Lecture.

Dr Andreas Fouras and his team have developed a unique respiratory imaging system, which aims to change the outcome for patients with lung disease.
 
In 2012, Andreas founded 4DMedical to commercialise the technology, which is now an ASX listed company.

In his keynote, Andreas illustrates his entrepreneurial journey, speaks about the highly innovative technology at 4DMedical and shares some of his thoughts about innovation in Australia

Over 320 guests comprising med tech executives, researchers, clinicians, government staff and investors attended the Bionics Institute 2023 Innovation Lecture to explore how Australia can accurately measure innovation, boost the med tech ecosystem and strengthen connections.

More information:

Watch the Bionics Institute 2023 Innovation Lecture recording

Visit the 4DMedical website

In the latest episode of Med Tech Talks, we present a special keynote speech from Kylie Walker, CEO of the Australian Academy of Technological Sciences and Engineering (ATSE), recorded at the Bionics Institute 2023 Innovation Lecture.

As CEO of ATSE, Kylie specialises in connecting technologists, engineers and scientists with governments, business, media and society with skills built over many years in senior federal communication and advocacy roles in science, technology and health sectors.

In her keynote, Kylie talks about using metrics to unlock the potential of Australian research and development, and the impact measuring innovation could have for the med tech sector.

Over 320 guests comprising med tech executives, researchers, clinicians, government staff and investors attended the Innovation Lecture to explore how Australia can accurately measure innovation, boost the med tech ecosystem and strengthen connections.

More information:

Watch the Bionics Institute 2023 Innovation Lecture recording

Visit the ATSE website

In the latest episode of Med Tech Talks, Robert Klupacs is joined by Professor Anne Kelso AO, CEO of the National Health and Medical Research Council (NHMRC). 

At NHMRC, Anne’s key focus areas have been the restructure of the organisation’s grant program, developments in NHMRC’s peer review processes, and progressing initiatives to improve gender equity in health and medical research.

This year, Anne will be stepping down as CEO of NHMRC after eight years. .

In this episode, you will hear about: 

• The role of the NHMRC in the Australian research ecosystem.
• Professor Kelso discussing some of the highlights of her career and the lessons she has learnt. 
• Some of the mentors she has had on her journey, including legendary Australian scientists Professor Sir Gustav Nossal AC and the late Professor Donald Metcalf AC.

Learn more about: 

• The NHMRC
• Professor Anne Kelso

Updated version 05/08/22

In this episode of Med Tech Talks, Robert Klupacs is joined by one of Australia’s most successful med tech expats, Dr Jeremy Buzzard,  CEO of Enteralia Bioscience and co-founder of Induction Bio.  

Jeremy also notably was a partner at McKinsey and Co., where he led the firm’s global healthcare strategy and corporate finance practice.

Jeremy is on the record as being involved in more than 25 major transactions that were executed with an aggregate value of $56Bn USD.

In this episode, you will hear about:

• The missions of Enteralia Biosciences and Induction Bio
• Jeremy's reflections on his time at Harvard University and McKinsey and Co.
•  His thoughts on the key learnings Australia can take from the US med tech market to improve our innovation outcomes.  

Learn more about:

• Enteralia Biosciences 

Updated version 05/08/22

Storytelling is an important part of successful innovation and entrepreneurship.  

Corrie McLeod is a med tech innovation and communications expert who understands the power of effective storytelling from her experience as founder and publisher at InnovationAus.  

InnovationAus is an independent publication that reports on the impact of government policy on Australia’s technology sectors, including financial services, cyber security, manufacturing and med tech ecosystems. 

In this episode you will hear: 

• The mission of InnovationAus and how this platform aims to galvanise innovation in Australia. 
• The importance of storytelling in the med tech commercialisation journey  
• Corries thoughts on how Australia should use innovation to boost the economy.   

Learn more: 

-          Take a look at the InnovationAus website

Updated version 05/08/22

The “valley of death” is often seen as a barrier to innovation. 

Dr Emma Ball, Head of Illumina for Startups (Australia, Asia Pacific, Middle East and Africa), challenges this idea on this week’s episode of Med Tech Talks. 

Dr Ball helps create and grow start-ups in the field of genomics and is an angel investor.

In this episode: 

• Hear the mission of Illumina and Illumina for Startups
• Learn what an angel investor looks for in a startup.
• Hear Dr Ball’s thoughts on how Australia can improve its innovation culture. 

Learn more about: 

• llumina for Startups grants
• Illumina

Updated version 05/08/22

Australia ranks 25th in the world for innovation as per the Global Innovation Index, but only ranks 32nd for translation of research. 

In this episode of Med Tech Talks, Robert Klupacs speaks with experienced med tech entrepreneur and founder of Chatsworth Associates, Andrew Maxwell, about what Australia should do to improve the translation of our research. 

Andrew has a remarkable record in the international business arena, with a history of successful company launches and business growth in the biotech sector. 

In this episode, you will hear about: 

• Andrew's career pathway that lead him to founding Chatsworth Associates, a boutique advisory firm providing strategic advice to emerging and high growth companies in the biomedical and med tech industry.
• Hear from Robert and Andrew as they discuss the roles that governments, industry and superannuation funds can play in boosting the med tech ecosystem as well as the impact that large companies can have in growing our economy. 
• His thoughts on the med tech ecosystem and the path forward for Australian innovation.

Learn more about: 

• Andrew Maxwell and the team at Chatsworth Associates.
• Chatsworth Associates

Updated version 05/08/22

Cochlear Ltd is an Australian med tech success story and a shining example of how we can build successful innovation in Australia. 

Established to commercialise the cochlear implant developed by Bionics Institute founder and bionic ear pioneer, Professor Graeme Clark and his research team, Cochlear holds 60% of the global cochlear implant market.

In this episode of Med Tech Talks, Robert Klupacs was joined by Dig Howitt, CEO and President of Cochlear Ltd and a renowned international leader in med tech.

Robert and Dig discuss how Cochlear’s mission is set to ensure continued leadership in the hearing implant landscape.  

They go on to explore what we can learn from the Cochlear blueprint to help build Australia from innovation.

In this episode, you will hear about:  

·         Dig’s journey to becoming CEO of Cochlear and his lessons in leadership

·         The mission of Cochlear Ltd and how they plan to avoid market disruption

·         How Australia can use the cochlear blueprint to improve the commercialisation of home-grown innovation.

More information: 

-          View the Cochlear Ltd website

-          Read the story of bionic ear pioneer, Professor Graeme Clark

Updated version 05/08/22

In this episode of Med Tech Talks, Robert Klupacs is joined by Alon Greenspan, Managing Partner at Mind Ventures.

Mind Ventures is touted as the world’s first mental health-focused for-profit venture fund. Seeded by the Black Dog Institute, Mind Ventures invests in scalable, evidence-based solutions across the mental health spectrum, from illness to well-being.

Alon has a wealth of international global tech M&A and venture capital experience, having previously worked at Jelix Ventures, Herzog Fox, and Arnold Bloch Liebler. With degrees in commerce and law, he is also an active angel investor and start-up advisor.

In this episode you will hear about:

• The mission of Mind Ventures and the need for innovations in mental health
• The role of an angel investor and the benefits for founders in connecting with them
• Alon’s advice for start ups and building long term relationships as an entrepreneur
• Lessons Alon has learned as an impact investor.

Learn more about Mind Ventures

Updated version 05/08/22

Engineering prowess is a key attribute when it comes to developing and commercialising a med tech device, but what attributes make a successful engineer? 
 
 In this episode of Med Tech Talks, Dr Paul Minty shares the one key attribute that elevates the best engineers above the rest in the med tech industry. 

Dr Paul Minty is COO of the highly innovative company, Deep Brain Stimulations Technologies Pty Ltd, which was established in 2019 to commercialise an adaptive deep brain stimulation system for Parkinson’s disease.

DBS Tech's system uses a novel brain signal called  Evoked Resonant Neural Activity (ERNA), to help surgeons implant electrodes in anaesthetised patients during Parkinson’s surgery with greater accuracy.

This will transform the experience of patients, as they currently need to be awake during surgery so that they can report on symptoms and guide placement of the electrode.

In this episode, you will hear about: 

• Paul’s unique career trajectory that has led to him becoming the COO of DBS Technologies.
• The incredible work being undertaken at DBS Technologies that aims to enhance the experience of deep brain stimulation for patients with Parkinson’s disease.
• His thoughts on the med tech ecosystem and the path forward for Australian innovation.
  
  

Learn more about: 

• Deep Brain Stimulation Technologies
• The research at DBS Tech

Updated version 05/08/22

Heart disease remains the leading cause of mortality worldwide, and many factors prevent clinicians from accurately predicting who is at risk of a heart attack. 

Professor Karlheinz Peter may have the solution that could save many lives.  

In this episode of Med Tech Talks, Robert Klupacs talks to internationally renowned interventional cardiologist Professor Karlheinz Peter, Deputy Director of the Baker Institute at the Alfred Hospital; and Chief Medical Officer at med tech company, Nirtek. 

Professor Peter and the team at Nirtek are developing intracoronary guidewire technology that can provide cardiologists with critical preventative health information. 

When steered into the arteries of the heart, their device aims to use near infrared light to identify dangerous, rupture-prone plaques before they lead to heart attacks. 

In this episode, you will hear about:  

• Professor Peter’s research into “intelligent drugs” and interventional cardiology that has spanned over 30 years.  
• How his team once foresaw an international pharmaceutical disaster 
• His insights into where further investment is needed in order to increase innovation in Australia 
• His learnings as a medical specialist, academic, researcher and entrepreneur

More information: 

Learn more about Professor Karlheinz Peter 

Find out more about Nirtek 

Read some publications from Professor Peter 

Updated version 05/08/22

A bionic eye implant might, at one stage, have seemed like something out of a science fiction movie.  

Not anymore.  

An Australian bionic eye shows promise of giving functional vision back to people who have lost their sight due to a genetic condition called retinitis pigmentosa. 

Being developed by Bionic Vision Technology (BVT), the bionic eye system came out of research at the Bionics Institute, the Centre for Eye Research Australia (CERA), CSIRO and ANU.  

In this episode of Med Tech Talks, Robert Klupacs is joined by BVT CEO Dr Ash Attia to discuss the research commercialisation journey of the bionic eye, and the upcoming large-scale clinical trials of this revolutionary technology. 

In this episode you will hear about:

• When will the bionic eye be available to patients?  
• Ash's insights on the difference between good and great companies
• Advice on how entrepreneurs should build a company to have lasting success.

More information:

Learn more about Bionic Vision Technologies.

Find out more about Dr Ash Attia and his team at BVT.

Learn about the development of Australia's Bionic eye.

Updated version 05/08/22

In this episode of Med Tech Talks, Robert Klupacs (CEO of the Bionics Institute) chats with Dr Ludovic Labat (CEO of Neo-Bionica) about how Australia should approach the global med tech market to increase our innovation output. 

Dr Labat is the inaugural CEO of Neo-Bionica, an initiative of the Bionics Institute and the University of Melbourne.  

Neo-Bionica is the first company of its kind in Australia, with the bioengineering expertise, specialised fabrication skills and regulatory experience required to create first-in-human prototypes for clinical trials. 

Specialising in neuromonitoring and neuromodulation technologies, Neo-Bionica aims to position Australia as leaders in medical device prototype and manufacturing.

In this episode you will hear about:

• Ludovic's journey to becoming CEO of the highly innovative start-up Neo-Bionica
• Neo-Bionica’s mission, and how its team can accelerate the journey to market for medical devices
• How Australia can better understand global markets to increase commercialisation success of our innovations.

More information:

Learn more about Neo-Bionica: Neo-Bionica

Find out more about Dr Ludovic Labat and his team at Neo-Bionica

Updated version 05/08/22

In this episode of Med Tech Talks, Robert Klupacs CEO of the Bionics Institute, chats with Sarah Meibusch, a partner at one of Australia’s largest venture capital firms, One Ventures, about the current life science venture capital climate and how industry stakeholders can best present their organisations to venture capitalists. 

Sarah Meibusch specialises in sourcing life science companies and, using her global entrepreneurial and executional experience, plays a key role in shaping their future. 

In this episode you will hear about:

• Sarah's journey to becoming a venture capitalist
• How industry stakeholders can best prepare themselves to be successful with venture capitalists
• Sarah's thoughts on the current VC climate in Australia
  
  

More information:

Take a look at One Ventures' website

Learn more about Sarah Meibusch here

Updated version 05/08/22

In this episode of Med Tech Talks, Robert Klupacs CEO of the Bionics Institute, chats with Professor Kate Hoy (Head of Cognitive Disorders Treatment Program, Bionics Institute) about how she is pioneering a treatment for Alzheimer’s disease using transcranial magnetic stimulation (TMS). 

Professor Hoy has built an internationally renowned program of clinical research investigating non-invasive brain stimulation. By stimulating key regions of the brain affected by Alzheimer’s disease, TMS offers the potential to restore healthy neural networks. 

In this episode you will hear about:

• Kate's journey to becoming an internationally renowned neuropsychologist
• What transcranial magnetic stimulation is and how it could be the key to resolving Alzheimer's disease
• Kate's thoughts on how scientists can become more effective communicators

More information:

Professor Hoy's Alzheimer's research is the focus of the Bionics Institute's Christmas appeal. To support our research, visit our Alzheimer's Christmas appeal.

Take a look at the Bionics Institute Alzheimer's research page: A new treatment for Alzheimer's

Learn more about Professor Kate Hoy: Professor Kate Hoy

Updated version 05/08/22

Over 200 prominent med tech executives, investors and researchers gathered to discuss why Australia lags behind so many other countries for med tech innovation, entrepreneurship and competitiveness. 

Hear how we can bridge the gap between research and commercialisation from our invited expert speakers and panelists:

- Dr Andrew Nash - Chief Scientific Officer, CSL

- Professor Michelle McIntosh - Director Medicines Manufacturing Innovation      Centre and Theme Leader at the Monash Institute of Pharmaceutical Sciences.

- Dr Megan O’Connor - Managing Director, Kantara Consulting

-  George Kenley - Chief Operating Officer, Seer Medical

More information
To find out more about commercialisation of research through medical device spin-off companies at the Bionics Institute, go to: Our Impact 

Updated version 05/08/22

In this episode of Med Tech Talks, Robert Klupacs CEO of the Bionics Institute, chats with Dr Megan O'Connor (founder and managing director of Kantara Consulting) about the economic opportunities supported by improved communication and collaboration between business, academia and political worlds in Australia.

Dr O’Connor established Kantara Consulting to support Australian life-science companies make an impact on the world. At the core of what she and her team does is communication – advocating for the biotech industry and helping organisations share details of their work with government, industry and investors. 

In this episode you will hear about:

• Megan's incredible PhD experience at Lund University, Sweden
• The foundation and mission of Kantara Consulting
• Megan's thoughts on how Australia can learn from international leader's policies to drive medical innovation

More information:
Take a look at the Kantara Consulting website: Kantara Consulting

To find out more about commercialisation of research through medical device spin-off companies at the Bionics Institute, go to: Our Impact 

Updated version 05/08/22

In this episode of Med Tech Talks, Robert Klupacs CEO of the Bionics Institute, a world leader in the development of medical devices, talks to Lusia Guthrie, an experienced company director, founder, former CEO, technology developer and med tech entrepreneur.

Listen to Lusia Guthrie as she describes herself as the 'accidental entrepreneur' detailing  her journey from the laboratory into industry where she founded LBT Innovations. Lusia commercialised a number of products and developed LBT Innovations into a global brand that now trades on the Australian stock exchange (ASX). 

Lusia is passionate about innovation and has a proven track record of driving concepts from early ideation stages through to commercial product launch. She is currently the inaugural Chair of Neo-Bionica. She is also Chair of the Australian Lung Health Initiative, Non-Executive Director at WearOptimo, and serves on several university and government industry advisory committees.

In this episode you will hear about:

• Lusia's journey from the laboratory bench to executive chair
• How chess can be used as a metaphor for driving successful business
• Lusia's thoughts on building Australia from innovation.

More information:
Take a look at Lusia Guthrie's biography on the Propper and Co website: Lusia Guthrie

Take a look at the Neo-Bionica website: Neo-Bionca

To find out more about commercialisation of research through medical device spin-off companies at the Bionics Institute, go to: Our Impact  

Updated version 05/08/22

In this episode of Med Tech Talks, Robert Klupacs CEO of the Bionics Institute, a world leader in the development of medical devices, talks to Professor Michelle McIntosh, Director of the  Medicines Manufacturing Innovation Centre and Theme Leader at the Monash Institute of Pharmaceutical Sciences. MIPS was recently named #1 in the QS world university rankings for pharmaceutical sciences for 2022. 

Professor McIntosh is an award-winning scientist who is known for her inhaled oxytocin research, which aims to transform maternal healthcare, particularly in developing countries where price, injecting capabilities and cold-storage capabilities may present barriers to safe and effective childbirth. 

Professor McIntosh's career has seen her win numerous awards, such as the Monash Vice-Chancellor’s award for Excellence in Research Impact . She has presented her work on inhaled oxytocin to the United Nations General Assembly in New York and her work was recognised  former US Secretary of State and presidential candidate, Hilary Clinton. 

In this episode you will hear about:

• Michelle's journey from PhD student to  acclaimed scientist at MIPS
• Some insights into her research and the potential of inhaled oxytocin to transform maternal healthcare in developing countries
• Michelle's thoughts on building Australia from innovation

More information:
Take a look at the Monash Institute of Pharmaceutical Sciences website: MIPS

Take a look at Professor Michelle McIntosh's Monash University Profile: Professor Michelle McIntosh

To find out more about commercialisation of research through medical device spin-off companies at the Bionics Institute, go to: Our Impact  

Updated version 05/08/22

In the latest episode of Med Tech Talks, Robert Klupacs is joined by Stephen Tomisich, Co-founder and CEO of Trajan Scientific and Medical.   

Based in Melbourne, Trajan develops and manufactures analytical science instruments, devices and solutions for health care, as well as for food and environment analysis – the only company of its kind listed on the ASX. 

Stephen has a strong acquisition strategy, having grown Trajan from a kitchen table concept in 2011 to a global collaborator. Over the last 13 years, Trajan has acquired twelve businesses across the US, Europe and Asia; developing Trajan’s key capabilities and product lines for emerging technologies.  

In this episode, you will hear more about: 

• Trajan’s unique business model and approach to acquisitions 
• How purpose, passion and an ‘all in’ mindset laid the foundations for global success
• Why it’s important to be your own threat as an innovator 
• Four books Stephen recommends entrepreneurs read.

Learn more about Trajan Scientific and Medical.

Stephen is a panellist at the upcoming Bionics Institute Innovation Lecture on 29 May in Melbourne. Learn more about the event and register your interest in attending.

Updated version 05/08/22

In this episode of Med Tech Talks, Robert Klupacs CEO of the Bionics Institute, a world leader in the development of medical devices, talks to leading neurologist Professor Mark Cook AO on his innovations to help predict and monitor seizures in patients with epilepsy. 

Professor Cook has been profoundly inspired to undertake a career in neurology through witnessing his father's struggles with epilepsy.

Through his internationally renowned research and the foundations of two MedTech companies, Seer Medical and Epi-Minder, Professor Cook has made a tremendous impact in the treatment of epilepsy. 

In this episode you will hear about:

• Professor Cook's research and innovations to better treat epilepsy
• The founding and mission of Seer Medical and Epi-Minder
• Mark's thoughts on building Australia from innovation

More information:
Read Mark Cook's biography : Professor Mark Cook

Take a look at the Epi-Minder website: Epi-Minder

Visit the Seer Medical website: Seer Medical

To find out more about commercialisation of research through medical device spin-off companies at the Bionics Institute, go to: Our Impact  

Updated version 05/08/22

In this episode of Med Tech Talks, Robert Klupacs CEO of the Bionics Institute, a world leader in the development of medical devices, talks to Professor David Grayden, Clifford Chair of Neural Engineering in the Department of Biomedical Engineering at the University of Melbourne 

Professor Grayden is a highly respected academic whose career has seen him work on flagship projects, including the cochlear implant in the bionic eye, epileptic seizure prediction, electrical stimulation devices and systems to prevent seizures and vagus nerve stimulation to control inflammatory bowel disease. 

More recently, Professor Grayden has pioneered the BioDesign Innovation program, a course offered by the University of Melbourne where teams of MBA and Master of Engineering students work together to explore, invent and commercialise medtech innovations.

In this episode you will hear about:

• David's journey to becoming  Clifford Chair of Neural Engineering in the Department of Biomedical Engineering at University of Melbourne
• The creation and importance of the BioDesign program to inspire future innovators
• David's thoughts on building Australia from innovation

More information:
Take a look at the BioDesign Innovation Melbourne website: BioDesign Innovation Melbourne

Take a look at Professor David Grayden's University of Melbourne Profile: Professor David Grayden

To find out more about commercialisation of research through medical device spin-off companies at the Bionics Institute, go to: Our Impact  

Updated version 05/08/22

In this episode of Med Tech Talks, Robert Klupacs CEO of the Bionics Institute, a world leader in the development of medical devices, talks to CEO of Synchron about the persistence and perspiration needed to build an innovative idea into a thriving med tech start-up, and gives advice to fellow entrepreneurs.

This series is dedicated to understanding what drives successful and impactful innovation in medical technology, and you would be hard-pressed to find someone as fitting for us to have as a guest on this podcast than Associate Professor Tom Oxley, who kindly joined us from New York. 

As well as being a renowned interventional neurologist at Mount Sinai Hospital in New York, Tom is the founder and CEO of Synchron, a company that specialises in neural interface technology.  Synchron was born from Tom’s great innovation, the Stentrode, an implantable medical device that can translate brain thought signals from the inside of a blood vessel.  

Thoughts captured from users of the stentrode are translated wirelessly digital devices designed to stimulate thought-controlled movement, which could transform the lives of people who are paralysed or have severely restricted movement. 

In this episode you will hear about:

• The story of Synchron
• Sourcing start-up funding and tips for people in med tech
• Tom's thoughts on building Australia from innovation 

More information
Take a look at the Synchron website: www.synchron.com

 To find out more about commercialisation of research through medical device spin-off companies at the Bionics Institute, go to: Our Impact  

Updated version 05/08/22

In this episode of Med Tech Talks, Robert Klupacs CEO of the Bionics Institute, a world leader in the development of medical devices, talks to his colleague Dr Erol Harvey about his amazing journey from cutting diamonds with lasers, modifying the Hubble telescope and founding the incredibly successful company MiniFAB.

Erol Harvey is CEO of the Aikenhead Centre for Medical Discovery (ACMD) that will soon be home to the Bionics Institute, alongside many other leading research organisations on the St Vincent's Hospital Melbourne campus, and he talks about the importance of collaboration.

We find out about Erol's amazing career in Europe before he returned to Australia to start a company, and his thoughts on what is needed to support innovation. 

In this episode you will hear about:

• Erol's work with huge lasers and the Hubble telescope
• What it takes to build a med tech company
• Erol's advice for developing the med tech ecosystem.

More information
Read about ACMD here: www.acmd.org.au

Take a look at the MiniFAB website here: www.schott-minifab.com

Take a look at the Bionics Institute website to find out more about our research into autoimmune and chronic conditions, and conditions affecting the brain, hearing and vision: Our Research | Bionics Institute

 To find out more about commercialisation of research through medical device spin-off companies at the Bionics Institute, go to: Our Impact  

Updated version 05/08/22

In this episode of Med Tech Talks, Robert Klupacs CEO of the Bionics Institute, a world leader in the development of medical devices, talks to his colleague Professor James Fallon about exciting innovations at the Bionics institute that build on the knowledge gained during development of the cochlear implant. 

As Chief Technology Officer and Head of Research Operations, James leads a broad range of research, including development of an innovative device that stimulates the vagus nerve to improve the lives of people with type 2 diabetes, rheumatoid arthritis and Crohn's disease. 

We find out about James' path from PhD student at the Bionics Institute to becoming a leading professor in bioengineering, and what he believes Australia can do to build greater innovation. 

In this episode you will hear about:

• How to always do what you love in your career and have fun along the way
• How the technology developed for the cochlear has given rise to new devices
• James' thoughts on building Australia from innovation.

More information
Take a look at the Bionics Institute website to find out more about our research into autoimmune and chronic conditions, and conditions affecting the brain, hearing and vision: Our Research | Bionics Institute

 To find out more about commercialisation of research through medical device spin-off companies at the Bionics Institute, go to: Our Impact  

Updated version 05/08/22

In the latest episode of Med Tech Talks, Robert Klupacs is joined by Dr Chris Smith, a partner at Brandon Capital - Australasia's leading life science venture capital firm.

Chris has extensive experience in the global biotech industry. With a PhD in immunology and an MBA specialising in innovation and entrepreneurship from the University of Cambridge; he has also previously been a business development manager with CSL; and is currently a Director of Aravax, Denteric, Ena Respiratory, MycRx, Q-Sera and Axelia Oncology, just to name a few.

In this episode, you will hear more about:

• Tips for pitching to investors and building a relationship with venture capital firms
• Demystifying the role of a VC in research and development
• Brandon Capital’s incubator approach to risk and investing in early-stage innovations.

Learn about Dr Chris Smith

Visit the Brandon Capital website

Updated version 05/08/22

In the latest episode of Med Tech Talks, Robert Klupacs is joined by Professor Steve Wesselingh, CEO of the National Health and Medical Research Council (NHMRC).

An infectious disease physician and researcher in HIV vaccine development and the impact of the microbiome on human health, Steve has a wealth of medical experience, clinical leadership, and national and international success.  

The NHMRC is Australia's lead agency, driving innovative health and medical research to improve the health of all Australians. 

Along with providing an ethical framework for health and medical research in our country, the NHMRC supports the discovery of new knowledge and its translation into public health, health services and medical products to improve health outcomes for all Australians.

In this episode you will hear about:

• Steve’s journey to becoming one of the world’s leading HIV researchers.
• The influence international experience in the US and Papua New Guinea had on his career
• Funding opportunities that could help Australia improve med tech or clinical outcomes
• Steve’s priorities as CEO of the NHMRC over the next 24 months and beyond, including government strategy input, and working more closely with the Australian Centre for Disease Control (CDC)

Learn more about Professor Steve Wesselingh 

Read more about the NHMRC.

Updated version 05/08/22

In the latest episode of Med Tech Talks, Robert Klupacs is joined by Dr Dean Freestone, Co-Founder of Seer Medical. 

A modern Australian innovation success story, Seer Medical was founded in 2017 and specialises in the early detection and diagnosis of epilepsy.  

The company has developed a highly innovative, portable video-EEG-ECG recording system that patients can take home with them, rather than being limited to hospital use. 

Dr Freestone was one of three co-founders of Seer and was CEO until 2023. Today, he holds a board position at Seer Medical.  

 In this episode you will hear about:   

• Dean’s unique journey from his school days all the way to being Co-Founder at Seer Medical. 
• How Seer Medical provides revolutionary new care and patient monitoring practices for patients with epilepsy. 
• The sacrifices and challenges Dean faced on the commericalisation journey to make Seer Medical a success. 

Learn more:  

Learn more about Dr Dean Freestone. 

Find out more about Seer Medical.

Updated version 05/08/22

In the latest episode of Med Tech Talks, Robert Klupacs is joined by the Honourable Jaala Pulford, Chair of MTPConnect, Vice Chancellor’s Fellow at the University of Melbourne, and former Minister of the Parliament of Victoria. 

Jaala is well known for her career in public service where she has held several significant portfolios, including Minister for Agriculture, Minister for Small Business and Minister for Innovation, Medical Research and the Digital Economy. 

In her role as Minister for Innovation, Medical Research and the Digital Economy, Jaala was at the forefront of agendas to boost Victoria’s innovation ecosystem including the $2 billion Breakthrough Victoria Fund and the securing of both Moderna and BioNTech vaccines for Melbourne. 

In this episode you will hear about:   

• Jaala’s career as a politician and her journey from Castlemaine, Victoria to the being a Minister in the Victorian Parliament. 
• Insights into her time as Minister for Innovation, Medical Research and the Digital Economy which coincided with the COVID-19 pandemic.  
• Her mission as Chair of MTPConnect and her thoughts on how Australia can improve its innovation ecosystem.  

Learn more: 

Learn more about Jaala Pulford. 

Find out more about MTPConnect.  
 

Updated version 05/08/22

In the latest episode of Med Tech Talks, Robert Klupacs is joined by Associate Professor Fiona Brownfoot, specialist obstetrician at the Mercy Hospital for Women, clinician scientist at the University of Melbourne and Co-Founder of Kali Healthcare.   

Kali Healthcare is undergoing an exciting commericalisation journey and aims to transform pregnancy monitoring through the development of a wearable device that will allow expecting mothers to monitor foetal heartbeats at home.  

In her role as Associate Professor of Obstetrics at the University of Melbourne, she heads the Obstetric Diagnostics and Therapeutics Group – a multidisciplinary team of scientists and engineers focused on developing new treatments for obstetric conditions – whilst mentoring PhD students to become the next generation of clinician scientists.
 
In this episode you will hear about:  

• How Kali Heathcare aims to improve foetal monitoring with new portable, wearable technology in order  to detect and prevent pregnancy complications 
• The commericalisation journey of Kali Healthcare 
• Fiona’s thoughts on the power of mentorship to propel the next generation of clinician scientists. 

More information:  

Learn more about Associate Professor Fiona Brownfoot. 

Read more about Kali Healthcare. 

Updated version 05/08/22

In the latest episode of Med Tech Talks, Robert Klupacs is joined by Dr Devinder Chauhan, a highly respected retinal ophthalmologist and Founding CEO of Macuject. 

Macuject is a digital health company that harnesses AI to provide imaging and data solutions for ophthalmologists to them make clinical decisions when treating age-related macular degeneration.  

Dr Chauhan founded Macuject in 2017 and is currently making the transition from clinician to entrepreneur as he and his team aim to roll this product out in eye clinics both domestically and internationally to improve visual outcomes for patients worldwide.
 
In this episode you will hear about: 

• Devinder’s career as a retinal ophthalmologist and why he founded Macuject 
• How Macuject aims to transform the treatment of age-related macular degeneration 
• The lessons Devinder has learned as he moved from the clinic to become an entrepreneur.  

More information: 

Learn more about Dr Devinder Chauhan. 

Read more about Macuject. 

Updated version 05/08/22

In this episode of Med Tech Talks, Robert Klupacs is joined by Dr Anne-Laure Puaux, inaugural CEO of WEHI Ventures and Head of Business Development at WEHI.

WEHI Ventures manages 66ten, a first of its kind pre-seed and seed strategic investment fund of $66 million, dedicated to ideas developed by or in collaboration with, WEHI. With a grand vision of investing $66 million over 10 years in groundbreaking medical innovations, 66ten is the largest internal pre-seed and seed fund created by an Australian medical research institute, established to bridge the gap between scientific discoveries and commercial viability.

Before joining WEHI, Anne-Laure worked in Europe, US, Asia and Australia as part of biotech companies and multinational pharmaceutical companies such as GSK. Through these roles, she gained extensive global experience designing, evaluating, negotiating, and closing deals between academic research institutions, biotech companies, private investors and large multinational companies. She has also completed a PhD in Immunology and an MBA. 

In this episode you will hear about:

• How WEHI Ventures is focusing on turning early-stage discoveries into commercial successes, and its strategic management approach to high-risk, high reward projects that may be too risky or too early-stage for traditional investors
• The importance of collaboration between academia and industry in translating early-stage discoveries into market-ready therapies
• Anne-Laure’s insights into how Australia needs to strengthen its innovation ecosystem to catalyse biotech commercialisation 
• The strategic importance of mentorship when opportunities to explore different career pathways may be limited.

Learn more about WEHI Ventures
Learn about Dr Anne-Laure Puaux

Updated version 05/08/22

In this episode of Med Tech Talks, Robert Klupacs is joined by Justin Zenanko, co-founder, CEO and president of SynerFuse™, a medical device company based in the United States developing an innovative solution to reduce chronic back pain and improve patient quality of life. 

Justin and his team have patented the SynerFuse e-TLIF™ procedure which aims to make traditional spine implant surgery more successful and cost effective by combining neuromodulation at the time surgeons are performing fusion back surgery. SynerFuse has completed a proof-of-concept study of 15 patients and they're coming up to a 12-month review of post-surgery results in October.

A certified public accountant, Justin has experience in corporate finance, entrepreneurship and startup development. He has previously led fundraising efforts resulting in $68 million of investment, including $34 million in angel funding and 34 million in Series A funding from a strategic investor. 

In this episode you will hear about:

• The global need to address opioid dependency by developing innovative drug-free treatments for chronic pain
• How SynerFuse’s e-TLIF technology stimulates the dorsal root ganglion as part of spinal fusion surgery – a world-first approach 
• How Justin and his co-founders overcame skepticism from specialists and the challenges of the COVID pandemic to get FDA approval on a feasibility study 
• Why Justin has invested his own money into SynerFuse and his advice to other unconventional entrepreneurs.

 Learn more about SynerFuse and the e-TLIF procedure.

Updated version 05/08/22

In this episode of Med Tech Talks, Robert Klupacs is joined by Dr Amir Zalcenstein, Managing Director of SYNthesis BioVentures. SYNthesis BioVentures is a registered early-stage venture Capital Limited partnerships fund, focused on early-stage therapeutics investing in projects from discovery through preclinical proof of concept and IND enabling studies. 

Amir and the team are investing in small molecule therapeutics, biologics and cell and gene therapies for conditions with significant unmet need. Their aim, to accelerate the development of cutting-edge therapies and technologies, ultimately improving patient outcomes and delivering value to their investors. 

Along with a PhD in molecular biology and an MBA, Amir has an extensive background in healthcare and international operations experience, having previously been head of business development for BiondVax, CEO of Amorphical and SoluBest, and a healthcare investment manager at OneVentures. 

In this episode you will hear about:

• How SYNthesis BioVentures is supporting early-stage research, 
• Opportunities to partner with overseas biotech firms and license underutilised, innovative therapies for western markets
• The challenges of financing biotech innovations, and the role of crossover funds in bridging early-stage investments with public markets 
• The importance of smart collaboration, and the need for startups to assemble a varied and knowledgeable team.

 Learn more about SYNthesis BioVentures

Updated version 05/08/22

In this episode of Med Tech Talks, Robert Klupacs is joined by Scott Kirkland, CEO and Managing Director of EMVision Medical Devices. 

EMVision (ASX:EMV)  is an ASX listed, Australian med tech company focused on developing portable brain imaging devices using electromagnetic (EM) technology. It was spun out of University of Queensland in 2017 and had its IPO in late-2018.

EMVision’s primary product is a portable scanner designed to quickly and non-invasively detect and monitor neurological conditions like stroke. 

Unlike traditional imaging methods such as CT or MRI, EMVision’s technology allows for bedside or on-the-go imaging, which can be particularly useful in emergency settings or in rural and remote locations to improve healthcare access.

Scott has a wealth of experience in the emerging tech both here and overseas, having previously been Head of Client Sales at Quantcast, a US-based technology company. He is also a member of the Australian Institute of Company Directors.

In this episode you will hear about:

• How EMVision is using ultra high frequency radio signals to differentiate stroke types, with the aim of speeding up diagnosis and treatment particularly within the first hour post-onset of a stroke
• Findings from the 300-patient trial* conducted in Australia, and the company’s plans for a pivotal US trial
• Learnings from EMVision’s capital raising, which led to a AUD$15M investment from Keysight Technologies
• The importance for startups to build strategic relationships early on and to utilise finite resources efficiently
• Scott’s advice for budding entrepreneurs and those seeking mentorship.

Learn more about Scott Kirkland and EMVision Medical Devices.

*EMVision released EMView study data subsequent to this recording, see ASX release ‘Algorithms deliver excellent results in EMView study’ 12th Nov.

Updated version 05/08/22

In this episode of Med Tech Talks, Robert Klupacs is joined by Dr Alastair Hick, Chief Commercialisation Officer at Monash University.

With a PhD in Chemical Ecology and an MBA from the Judge Business School at the University of Cambridge, Alastair has a wealth of experience both in Australian and overseas markets and brings an ecosystem approach to commercialisation and innovation.

At Monash University, Alastair has been responsible has developed a successful IP commercialisation program and an also oversees The Generator, a hub that develops the entrepreneurial talent of Monash’s students, staff, and alumni. 

Alastair has recently established a $15 million Monash/Breakthrough Victoria Pre-Seed fund and is chair of its investment committee. He was also a founding director of the $30 million Trans-Tasman Commercialisation Fund; is a director of Monash University spinouts Jupiter Ionics, Phrenix Therapeutics, Myostellar and Flex Immunotherapeutics; as well as an early-stage investor Uniseed and therapeutics development company BioCurate.

In this episode, you will learn from Alastair about: 

• The evolution of the commercialisation ecosystem at Monash University 
• The role of entrepreneurial talent in innovation success
• Challenges in scaling and accessing investment
• Potential role of the government in supporting Australian innovation
• The importance of mentorship and confidence in entrepreneurship.

Learn more about Dr Alastair Hick.

Learn more about The Generator.

Updated version 05/08/22

In this latest episode of Med Tech Talks, Robert Klupacs is joined by Brendon Gardner, CEO of The Royal Victorian Eye and Ear Hospital (Eye and Ear) in Melbourne.

The Royal Victorian Eye and Ear Hospital is Australia’s only specialist eye, ear, nose and throat hospital and has been operating since 1863.

The Eye and Ear sees over 250,000 patients a year and offers over 110 different outpatient clinics for the diagnosis, monitoring and treatment of vision and hearing loss. The hospital also has a 24-hour emergency department for patients requiring urgent care and treatment.

Brendon Gardner first joined the Victorian Public Health care system in 1990 as a Health Information Manager and over the following 35 years, has held a variety of roles including 9 years as Chief Operating Officer of Peninsula Health. In 2019, he was appointed as CEO of the Eye and Ear.

In this episode, you will learn from Brendon about:

• Brendon’s journey to becoming CEO of a major hospital in Australia
• The mission and legacy of the Eye and Ear
• Brendon’s objectives for the future of the Eye and Ear.

Learn more about Brendon Gardner and the executive team at the Eye and Ear Hospital.

Learn more about the Royal Victorian Eye and Ear Hospital.

Updated version 05/08/22